Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.

Date publication

janvier 2017

Journal

Inflammatory bowel diseases

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Roblin X, Duru G, Williet N, Del Tedesco E, Cuilleron M, Jarlot C, Phelip JM, Boschetti G, Flourié B, Nancey S, Peyrin-Biroulet L, Paul S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28002129

Résumé

The best noninvasive method predicting clinical relapse remains undetermined in infliximab (IFX)-treated patients with Crohn's disease.

Mots clés

Adult, Azathioprine, administration & dosage, C-Reactive Protein, analysis, Crohn Disease, diagnosis, Feces, chemistry, Female, Gastrointestinal Agents, administration & dosage, Humans, Infliximab, administration & dosage, Leukocyte L1 Antigen Complex, analysis, Logistic Models, Maintenance Chemotherapy, methods, Male, Middle Aged, Predictive Value of Tests, Prospective Studies, Recurrence, Severity of Illness Index, Treatment Outcome

Référence

Inflamm. Bowel Dis.. 2017 01;23(1):126-132